Metabolite-P450 complex formation by methylenedioxyphenyl HIV protease inhibitors in rat and human liver microsomes

Biochemical Pharmacology

Volumn 56, Issue 2, 1998, Pages 223-230

  Chiba, Masato ^a   Nishime, Joy A ^a   Chen, I Wu ^a   Vastag, Kari J ^a   Sahly, Yousif S ^a   Kim, Byeong Moon ^a   Dorsey, Bruce D ^a   Vacca, Joseph P ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CYP2D; CYP3A; MI complex; P450

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN TISSUE; KINETICS; LIVER MICROSOME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYLATION; ISOENZYMES; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031757193     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00139-7     Document Type: Article

References (23)

1. Saville BA, Gray MR and Tam YK, Evidence for lidocaine-induced enzyme inactivation. J Pharm Sci 78: 1003-1008, 1989.
2. Gray MR and Tam YK, Pharmacokinetics of drugs that inactivate metabolic enzymes. J Pharm Sci 80: 121-127, 1991.
3. Hussain MD, Tam YK, Gray MR and Coutts RT, Mechanism of time-dependent kinetics of diltiazem in the isolated perfused rat liver. Drug Metab Dispos 22: 36-42, 1994.
4. Murray M and Reidy GF, Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42: 85-101, 1990.
5. Philpot RM and Hodgson E, A cytochrome P-450-piperonyl butoxide spectrum similar to that produced by ethyl isocyanide. Life Sci 10(Part II): 503-512, 1971.
6. Philpot RM and Hodgson E, The production and modification of cytochrome P-450 difference spectra by in vivo administration of methylenedioxyphenyl compounds. Chem Biol Interact 4: 185-194, 1972.
7. Dahl AR and Hodgson E, The interaction of aliphatic analogs of methylenedioxyphenyl compounds with cytochromes P450 and P420. Chem Biol Interact 27: 163-175, 1979.
8. Wilkinson CF, Murray M and Marcus CB, Interactions of methylenedioxyphenyl compounds with cytochrome P450 and effects on microsomal oxidation. In: Reviews in Biochemical Toxicology (Eds. Hodgson JR, Bend JR and Philpot RM), Vol. 6, pp. 27-63. Elsevier, Amsterdam, 1984.
9. Dickins M, Elcombe CR, Moloney SJ, Netter KJ and Bridges JW, Further studies on the dissociation of the isosafrole metabolite-cytochrome P450 complex. Biochem Pharmacol 28: 231-238, 1979.
10. Murray M, Wilkinson CF, Marcus C and Dube CE, Structure-activity relationships in the interactions of alkoxymethylenedioxybenzene derivatives with rat hepatic microsomal mixed-function oxidase in vivo. Mol Pharmacol 24: 129-136, 1983.
11. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
12. Correia MA, Rat and human liver cytochromes P450: Substrate and inhibitor specificities and functional markers. In: Cytochrome P450 (Ed. Oritz de Montellano PR), pp. 607-630. Plenum Press, New York, 1995.
13. Chiba M, Nishime JA and Lin JH, Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275: 1527-1534, 1995.
14. Chiba M, Hensleigh M, Nishime JA, Balani SK and Lin JH, Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24: 307-314, 1996.
15. Chiba M, Hensleigh M and Lin JH, Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 53: 1187-1195, 1997.
16. Bensoussan C, Delaforge M and Mansuy D, Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of amino-drugs. Biochem Pharmacol 49: 591-602, 1995.
17. Mansuy D, Battioni JP, Chottard JC and Ullrich V, Preparation of a porphyrin-iron-carbene model for the cytochrome P-450 complexes obtained upon metabolic oxidation of the insecticide synergists of the 1,3-benzodioxole series. J Am Chem Soc 101: 3971-3973, 1979.
18. Yu L-S, Wilkinson CF and Anders MW, Generation of carbon monoxide during the microsomal metabolism of methylenedioxyphenyl compounds. Biochem Pharmacol 29: 1113-1122, 1980.
19. Murray M, Hetnarski K and Wilkinson CF, Selective inhibitory interactions of alkoxymethylenedioxybenzenes towards mono-oxygenase activity in rat-hepatic microsomes. Xenobiotica 15: 369-379, 1985.
20. Murray M, Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol Pharmacol 42: 931-938, 1992.
21. Sinai CJ and Bend JR, Isozyme-selective metabolic intermediate complex formation of guinea pig hepatic cytochrome P450 by N-alkylated derivatives of 1-aminobenzotriazole. Chem Res Toxicol 8: 82-91, 1995.
22. Lin JH, Chiba M, Chen I-W, Vastag KJ, Nishime JA, Dorsey BD, Michelson SR and McDaniel SL, Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J Pharmacol Exp Ther 274: 264-269, 1995.
23. Sahalisahly Y, Balani SK, Lin JH and Baillie TA, In-vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome-P450 3A4. Chem Res Toxicol 9: 1007-1012, 1996.